United States · 
Who invested in Edgemont Pharmaceuticals?
Edgemont Pharmaceuticals's investors include Oxford Finance LLC.
20112012201320142015
$4.8MVenture?DebtUnited States · Funded startup
Who invested in Edgemont Pharmaceuticals
Funding summaryUpdated 26 Oct 2026
$4.8Mraised across 2 rounds since 2010, from 2 sources
- Latest round
- DebtMay 2015
- Biggest round
- $4.8MVenture · Dec 2010
- Investors
- 1
The funding story
Each circle is a round, placed by date and sized by amount. The line above is the running total.
- First round
- Venture, $4.8M Dec 2010
- Biggest round
- $4.8M Venture · Dec 2010
- Between rounds
- 4.4 years from the last two
The rounds
- May 2015
- Dec 2010Venture$4.8M
No investor was named in the report.
From a historical funding recordSEC filing: $4.8M sold, first sale Mar 2010
Founders and team
From the SEC filings it signed: 1 founder.
Douglas A. SaltelFounder of Company.Named on its 2010 Form Di
On the board, as filediBarbara A. DuncanRobert A. ZerbeTimothy A. McInerney
Everyone who backed them
Missing a round, or an investor who was in one? Tell us.
Quick answers about Edgemont Pharmaceuticals
How much has Edgemont Pharmaceuticals raised?
Edgemont Pharmaceuticals has raised $4.8M across 2 rounds since 2010. One round did not disclose an amount, so the total is a floor.
When did Edgemont Pharmaceuticals last raise?
Edgemont Pharmaceuticals's most recent round was a Debt in May 2015.
What was Edgemont Pharmaceuticals's biggest round?
Edgemont Pharmaceuticals's largest round on record is $4.8M (Venture), in Dec 2010.
Who backed Edgemont Pharmaceuticals first?
Edgemont Pharmaceuticals's first round on record, in May 2015, was backed by Oxford Finance LLC.
What stage is Edgemont Pharmaceuticals at?
Edgemont Pharmaceuticals's latest named round is a Debt, in May 2015.
Where is Edgemont Pharmaceuticals based?
Edgemont Pharmaceuticals is based in the United States.
Companies like Edgemont Pharmaceuticals
In the same sector, and raised in the last eighteen months.
Find investors like these
Search every investor by what they have actually funded, then narrow to your stage and market. Free.